E Cossu1, M Incani1, M G Pani1, G Gattu1, C Serafini1, A Strazzera1, L Bertoccini2, F A Cimini2, I Barchetta2, M G Cavallo2, M G Baroni3,4. 1. Endocrinology and Diabetes, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. 2. Department of Experimental Medicine, Sapienza University of Rome, Policlinico Umberto I, 00161, Rome, Italy. 3. Department of Experimental Medicine, Sapienza University of Rome, Policlinico Umberto I, 00161, Rome, Italy. marco.baroni@uniroma1.it. 4. Endocrinology and Diabetes, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. marco.baroni@uniroma1.it.
Abstract
PURPOSE: Gestational diabetes mellitus (GDM) is the most frequent complication of pregnancy; around 10% of GDM cases may be determined by autoimmunity, and our aims were to establish the role of autoimmunity in a population of Sardinian women affected by GDM, to find predictive factors for autoimmune GDM, and to determine type 1 diabetes (T1D) auto-antibodies (Aabs) together with glucose tolerance after a mean 21.2 months of follow-up. METHODS: We consecutively recruited 143 women affected by GDM and 60 without GDM; clinical data and pregnancy outcomes were obtained by outpatient visit or phone recall. T1D auto-antibodies GADA, IA2-A, IAA, ZnT8-A were measured in the whole population at baseline, and in the Aab-positive women at follow-up. RESULTS: The overall prevalence of autoimmunity was 6.4% (13/203). No significant difference was found in the prevalence of auto-antibodies between GDM (5.6%) and control (8.3%) women, neither in antibody titres. Highest titres for GADA and ZnT8-A were observed in the control group; no phenotypic factors were predictive for autoimmune GDM. Diabetes-related autoantibodies were still present in all the GDM women at follow-up, and their presence was associated with a 2.65 (p < 0.0016) relative risk (RR) of glucose impairment. CONCLUSION: We observed a low prevalence (5.6%) of diabetes-related autoimmunity in our GDM cohort, consistent with the prevalence reported in previous studies. It was not possible to uncover features predictive of autoimmune GDM. However, given the significant risk of a persistent impaired glycemic regulation at follow-up, it is advisable to control for glucose tolerance in GDM women with diabetes-related autoimmunity.
PURPOSE:Gestational diabetes mellitus (GDM) is the most frequent complication of pregnancy; around 10% of GDM cases may be determined by autoimmunity, and our aims were to establish the role of autoimmunity in a population of Sardinian women affected by GDM, to find predictive factors for autoimmune GDM, and to determine type 1 diabetes (T1D) auto-antibodies (Aabs) together with glucose tolerance after a mean 21.2 months of follow-up. METHODS: We consecutively recruited 143 women affected by GDM and 60 without GDM; clinical data and pregnancy outcomes were obtained by outpatient visit or phone recall. T1D auto-antibodies GADA, IA2-A, IAA, ZnT8-A were measured in the whole population at baseline, and in the Aab-positive women at follow-up. RESULTS: The overall prevalence of autoimmunity was 6.4% (13/203). No significant difference was found in the prevalence of auto-antibodies between GDM (5.6%) and control (8.3%) women, neither in antibody titres. Highest titres for GADA and ZnT8-A were observed in the control group; no phenotypic factors were predictive for autoimmune GDM. Diabetes-related autoantibodies were still present in all the GDM women at follow-up, and their presence was associated with a 2.65 (p < 0.0016) relative risk (RR) of glucose impairment. CONCLUSION: We observed a low prevalence (5.6%) of diabetes-related autoimmunity in our GDM cohort, consistent with the prevalence reported in previous studies. It was not possible to uncover features predictive of autoimmune GDM. However, given the significant risk of a persistent impaired glycemic regulation at follow-up, it is advisable to control for glucose tolerance in GDM women with diabetes-related autoimmunity.
Entities:
Keywords:
Autoantibodies; Follow-up; GADA; IA2-A; Type 1 diabetes; ZnT8
Authors: H Wucher; J Lepercq; C Carette; C Colas; D Dubois-Laforgue; J-F Gautier; D Lalej; E Larger; S Ledoux; J Mbemba; H Mosnier-Pudar; L Piétri; A Saltiel; A Sola; J Timsit Journal: Diabetes Metab Date: 2010-12-03 Impact factor: 6.041
Authors: Ilkka Y Järvelä; Jaana Juutinen; Pentti Koskela; Anna-Liisa Hartikainen; Petri Kulmala; Mikael Knip; Juha S Tapanainen Journal: Diabetes Care Date: 2006-03 Impact factor: 19.112
Authors: A Lapolla; D Fedele; B Pedini; M G Dal Fra; M Sanzari; M Masin; R Zanchetta; C Betterle Journal: Ann N Y Acad Sci Date: 2002-04 Impact factor: 5.691
Authors: M Incani; C Serafini; C Satta; L Perra; F Scano; P Frongia; R Ricciardi; C Ripoli; M Soro; A Strazzera; S Zampetti; R Buzzetti; M G Cavallo; E Cossu; M G Baroni Journal: Diabetes Metab Res Rev Date: 2016-11-30 Impact factor: 4.876
Authors: F Cucca; F Muntoni; R Lampis; F Frau; L Argiolas; M Silvetti; E Angius; A Cao; S De Virgiliis; M Congia Journal: Hum Immunol Date: 1993-06 Impact factor: 2.850
Authors: Kaat Beunen; Lies Vercauter; Paul Van Crombrugge; Carolien Moyson; Johan Verhaeghe; Sofie Vandeginste; Hilde Verlaenen; Chris Vercammen; Toon Maes; Els Dufraimont; Nele Roggen; Christophe De Block; Yves Jacquemyn; Farah Mekahli; Katrien De Clippel; Annick Van Den Bruel; Anne Loccufier; Annouschka Laenen; Roland Devlieger; Chantal Mathieu; Katrien Benhalima Journal: Front Endocrinol (Lausanne) Date: 2022-08-24 Impact factor: 6.055